Mohamed Al-Ghannam, CEO of Avalon Pharma
He mentioned Muhammad Al-GhannamCEO of the corporate Avalon PharmaThe corporate will proceed to attain passable ends in the fourth quarter of this yr, anticipating the export sector to witness the best progress charges throughout the fourth quarter, pushed by the seasonality of gross sales and the signing of recent overseas agreements.
Al-Ghannam added, in an interview with Al-Arabiya TV, commenting on: Monetary outcomes The corporate acknowledged that the decline in revenue margins within the third quarter of 2025 is because of seasonal elements associated to the character of the merchandise and market motion, and has no relation to the corporate’s efficiency.
Al-Ghannam defined that the corporate’s ends in the third quarter of 2025 recorded vital progress in comparison with the identical interval final yr, regardless of seasonal fluctuations in some merchandise.
Based on knowledge numbersAvalon Pharma’s income rose to 52.5 million riyals by the tip of the primary 9 months of 2025 by 50%, in comparison with income of 35 million riyals achieved throughout the identical interval in 2024, whereas third-quarter income elevated by about 114% to eight.3 million riyals.
The corporate attributed the rationale for the rise in income throughout the third quarter of 2025 on an annual foundation to the rise in revenues by 33%, reaching 107.95 million riyals, because of the noticeable enhance in gross sales from the personal and export sectors by 61% and 11%, respectively.
